Literature DB >> 17938926

Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.

J Zuckermann1, L B Moreira, P Stoll, L M Moreira, R S Kuchenbecker, C A Polanczyk.   

Abstract

Febrile neutropenia is associated with significant morbidity and mortality. Managing infectious in neutropenic patients remains a dynamic process, making necessary timely and efficient empirical antibiotic therapy. The implementation of critical pathways has been suggested as a strategy to improve clinical effectiveness. This study evaluated the compliance with an institutional critical pathway for the management of febrile neutropenia and the impact on clinical outcomes at Hospital de Clínicas de Porto Alegre, Brazil (HCPA). We performed a cohort study that prospectively included patients hospitalized from January 2004 to December 2005 and presented febrile neutropenia (190 episodes). Historical controls were selected from March 2001 to April 2003 (193 episodes) before the critical pathway was introduced. This study showed a low rate of full compliance (21.6%; 95% CI 15.7-27.5) with the critical pathway. In most cases, there was partial compliance (67.9%; 95% CI 61.3-74.5). Despite the moderate adherence observed, we recorded a decrease in in-hospital all-cause mortality in the sample studied after protocol implementation (from 24.4 to 14.4%; P = 0.017) and reduction in the length of use of cephalosporin and quinolones. In conclusion, implementation of a critical pathway seems to be an effective strategy to improve clinical outcomes in patients hospitalized with febrile neutropenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938926     DOI: 10.1007/s00277-007-0390-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

1.  Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.

Authors:  Lisa M Daniels; Urshila Durani; Jason N Barreto; John C O'Horo; Mustaqeem A Siddiqui; John G Park; Pritish K Tosh
Journal:  Support Care Cancer       Date:  2019-02-25       Impact factor: 3.603

2.  Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.

Authors:  Byuk Sung Ko; Shin Ahn; Yoon-Seon Lee; Won Young Kim; Kyung Soo Lim; Jae-Lyun Lee
Journal:  Support Care Cancer       Date:  2015-02-10       Impact factor: 3.603

3.  Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population.

Authors:  John C O'Horo; Jasmine R Marcelin; Omar M Abu Saleh; Amelia K Barwise; Patricia M Odean; Christina G Rivera; Aaron J Tande; John W Wilson; Douglas R Osmon; Pritish K Tosh
Journal:  J Oncol Pract       Date:  2019-07-19       Impact factor: 3.840

4.  Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.

Authors:  Matthew Ziegler; Daniel Landsburg; David Pegues; Warren Bilker; Cheryl Gilmar; Colleen Kucharczuk; Theresa Gorman; Kristen Bink; Amy Moore; Rebecca Fitzpatrick; Edward A Stadtmauer; Patricia Mangan; Kelly Kraus; Jennifer H Han
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

5.  Symptom to door interval in febrile neutropenia: perspective in India.

Authors:  Sapna Oberoi; Amita Trehan; R K Marwaha; Deepak Bansal
Journal:  Support Care Cancer       Date:  2012-12-15       Impact factor: 3.603

Review 6.  The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2013-02-27       Impact factor: 3.603

7.  Current State of Antimicrobial Stewardship at Solid Organ and Hematopoietic Cell Transplant Centers in the United States.

Authors:  Susan K Seo; Kaming Lo; Lilian M Abbo
Journal:  Infect Control Hosp Epidemiol       Date:  2016-07-26       Impact factor: 3.254

8.  Improving hospital performance in the treatment of febrile neutropenia.

Authors:  Barry Meisenberg; Jan Clemons; John Ness; Nancy Faust; Mary Clance
Journal:  Support Care Cancer       Date:  2014-08-09       Impact factor: 3.603

9.  Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting.

Authors:  Sheena Mukkada; Cristel Kate Smith; Delta Aguilar; April Sykes; Li Tang; Mae Dolendo; Miguela A Caniza
Journal:  Pediatr Blood Cancer       Date:  2017-09-12       Impact factor: 3.167

Review 10.  Advances in the treatment of neutropenia.

Authors:  David C Dale
Journal:  Curr Opin Support Palliat Care       Date:  2009-09       Impact factor: 2.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.